New pill hopes to slow Alzheimer's in major trial
NCT ID NCT07191028
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 23 times
Summary
This Phase 3 study tests whether MLC901 (NeuroAiD II) can slow cognitive decline in people with mild to moderate Alzheimer's disease. About 350 participants will receive either the drug or a placebo for several months. Researchers will measure changes in memory, thinking, and daily function, along with blood biomarkers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE DEMENTIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National University Hospital Singapore
Singapore, Singapore
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.